Advertisement

Supportive Care in Cancer

, Volume 27, Issue 1, pp 23–32 | Cite as

Reproductive health care across the lifecourse of the female cancer patient

  • Lisa A. Rubinsak
  • Mindy S. Christianson
  • Aletha Akers
  • Jeanne Carter
  • Andrew M. Kaunitz
  • Sarah M. Temkin
Review Article

Abstract

Reproductive health is a key component of cancer care and survivorship, encompassing gynecologic issues ranging from contraception and fertility to treatment of sexual dysfunction and menopause. Yet, oncology providers are often unfamiliar with the management of gynecologic issues. In order to address the unmet needs of female cancer patients, reproductive health should be addressed at the time of cancer diagnosis and continue through survivorship. Universal screening for pregnancy intention can guide counseling on contraception and fertility preservation. Safe and efficacious contraceptive options for both patients undergoing active treatment and cancer survivors are available and can often offer non-contraceptive benefits such as regulation of menses. Prompt referral to reproductive endocrinology specialists allows patients to explore options for fertility preservation prior to the receipt of cancer-directed therapies. Due to a rapid drop in hormone levels, treatment-induced menopause often results in severe symptoms. In patients with induced menopause, balancing the risks of hormone therapy compared to the decreased quality of life and health concerns associated with early menopause may help patients with difficult decisions regarding symptom control. Cancer treatment impacts sexual function with both physical changes to the vulvovaginal tissues and altered relationship dynamics. Open discussions on the impact to sexual health are paramount to quality of life after cancer. While more data is needed in many areas, proactive management of reproductive health issues is crucial to quality of life in cancer survivorship. In this article, we review contemporary management of the reproductive health of the female cancer patient.

Keywords

Cancer survivorship Reproductive health 

References

  1. 1.
    Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2017) SEER cancer statistics review, 1975-2014. Available from: https://seer.cancer.gov/csr/1975_2014/ based on November 2016 SEER data submission, posted to the SEER web site
  2. 2.
    Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Quinn G, Wallace WH, Oktay K, American Society of Clinical Oncology (2013) Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31(19):2500–2510CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    McLaren JF, Bates GW (2012) Fertility preservation in women of reproductive age with cancer. Am J Obstet Gynecol 207(6):455–462CrossRefPubMedGoogle Scholar
  4. 4.
    Angarita AM et al (2016) Fertility preservation: a key survivorship issue for young women with cancer. Front Oncol 6:102CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Präg P, Mills MC (2017) Assisted reproductive technology in Europe: usage and regulation in the context of cross-border reproductive care. In: Kreyenfeld M, Konietzka D (eds) Childlessness in Europe: contexts, causes, and consequences. Springer International Publishing, Cham, pp 289–309CrossRefGoogle Scholar
  6. 6.
    Dolmans MM, Hollanders de Ouderaen S, Demylle D, Pirard C (2015) Utilization rates and results of long-term embryo cryopreservation before gonadotoxic treatment. J Assist Reprod Genet 32(8):1233–1237CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Practice Committees of American Society for Reproductive, M. and T. Society for Assisted Reproductive (2013) Mature oocyte cryopreservation: a guideline. Fertil Steril 99(1):37–43CrossRefGoogle Scholar
  8. 8.
    Boiso I, Marti M, Santalo J, Ponsa M, Barri PN, Veiga A (2002) A confocal microscopy analysis of the spindle and chromosome configurations of human oocytes cryopreserved at the germinal vesicle and metaphase II stage. Hum Reprod 17(7):1885–1891CrossRefPubMedGoogle Scholar
  9. 9.
    Papatheodorou A, Vanderzwalmen P, Panagiotidis Y, Prapas N, Zikopoulos K, Georgiou I, Prapas Y (2013) Open versus closed oocyte vitrification system: a prospective randomized sibling-oocyte study. Reprod BioMed Online 26(6):595–602CrossRefPubMedGoogle Scholar
  10. 10.
    Rienzi L, Cobo A, Paffoni A, Scarduelli C, Capalbo A, Vajta G, Remohi J, Ragni G, Ubaldi FM (2012) Consistent and predictable delivery rates after oocyte vitrification: an observational longitudinal cohort multicentric study. Hum Reprod 27(6):1606–1612CrossRefPubMedGoogle Scholar
  11. 11.
    Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z (2005) Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 23(19):4347–4353CrossRefPubMedGoogle Scholar
  12. 12.
    Cakmak H, Katz A, Cedars MI, Rosen MP (2013) Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril 100(6):1673–1680CrossRefPubMedGoogle Scholar
  13. 13.
    Resetkova N, Hayashi M, Kolp LA, Christianson MS (2013) Fertility preservation for prepubertal girls: update and current challenges. Curr Obstet Gynecol Rep 2(4):218–225CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Donnez J, Dolmans MM, Demylle D, Jadoul P, Pirard C, Squifflet J, Martinez-Madrid B, van Langendonckt A (2004) Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 364(9443):1405–1410CrossRefPubMedGoogle Scholar
  15. 15.
    Donnez J, Dolmans MM (2017) Fertility preservation in women. N Engl J Med 377(17):1657–1665CrossRefPubMedGoogle Scholar
  16. 16.
    Visvanathan DK, Cutner AS, Cassoni AM, Gaze M, Davies MC (2003) A new technique of laparoscopic ovariopexy before irradiation. Fertil Steril 79(5):1204–1206CrossRefPubMedGoogle Scholar
  17. 17.
    Elizur SE, Tulandi T, Meterissian S, Huang JYJ, Levin D, Tan SL (2009) Fertility preservation for young women with rectal cancer--a combined approach from one referral center. J Gastrointest Surg 13(6):1111–1115CrossRefPubMedGoogle Scholar
  18. 18.
    Green DM, Whitton JA, Stovall M, Mertens AC, Donaldson SS, Ruymann FB, Pendergrass TW, Robison LL (2002) Pregnancy outcome of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Am J Obstet Gynecol 187(4):1070–1080CrossRefPubMedGoogle Scholar
  19. 19.
    Gambino A, Gorio A, Carrara L, Agoni L, Franzini R, Lupi GP, Maggino T, Romagnolo C, Sartori E, Pecorelli S (2011) Cancer in pregnancy: maternal and fetal implications on decision-making. Eur J Gynaecol Oncol 32(1):40–45PubMedGoogle Scholar
  20. 20.
    Mody SK et al (2017) Contraception concerns, utilization and counseling needs of women with a history of breast cancer: a qualitative study. Int J Womens Health 9:507–512CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Bellanca HK, Hunter MS (2013) ONE KEY QUESTION(R): preventive reproductive health is part of high quality primary care. Contraception 88(1):3–6CrossRefPubMedGoogle Scholar
  22. 22.
    Patel A, Schwarz EB, P. Society of Family (2012) Cancer and contraception. Release date May 2012. SFP Guideline #20121. Contraception 86(3):191–198CrossRefPubMedGoogle Scholar
  23. 23.
    Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, Simmons KB, Pagano HP, Jamieson DJ, Whiteman MK (2016) U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep 65(3):1–103CrossRefPubMedGoogle Scholar
  24. 24.
    Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM (2016) Progestin-only contraception and thromboembolism: a systematic review. Contraception 94(6):678–700CrossRefPubMedGoogle Scholar
  25. 25.
    Curtis KM, Peipert JF (2017) Long-acting reversible contraception. N Engl J Med 376(5):461–468CrossRefPubMedGoogle Scholar
  26. 26.
    Westrom L (1980) Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. Am J Obstet Gynecol 138(7 Pt 2):880–892CrossRefPubMedGoogle Scholar
  27. 27.
    Maslow BS et al (2014) Contraceptive use and the role of contraceptive counseling in reproductive-aged women with cancer. Contraception 90(1):79–85CrossRefPubMedGoogle Scholar
  28. 28.
    Casey PM, Faubion SS, MacLaughlin K, Long ME, Pruthi S (2014) Caring for the breast cancer survivor’s health and well-being. World J Clin Oncol 5(4):693–704CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Dinger J, Bardenheuer K, Minh TD (2011) Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception 83(3):211–217CrossRefPubMedGoogle Scholar
  30. 30.
    Trinh XB, Tjalma WAA, Makar AP, Buytaert G, Weyler J, van Dam PA (2008) Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril 90(1):17–22CrossRefPubMedGoogle Scholar
  31. 31.
    Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS (2008) The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care 13 Suppl 1:13–28CrossRefPubMedGoogle Scholar
  32. 32.
    (2014) Committee opinion no. 606: options for prevention and management of heavy menstrual bleeding in adolescent patients undergoing cancer treatment. Obstet Gynecol 124(2 Pt 1): 397–402Google Scholar
  33. 33.
    Meirow D, Rabinovici J, Katz D, Or R, Shufaro Y, Ben-Yehuda D (2006) Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate. Cancer 107(7):1634–1641CrossRefPubMedGoogle Scholar
  34. 34.
    Denlinger CS, Sanft T, Baker KS, Baxi S, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, King A, Koura D, Kvale E, Lally RM, Langbaum TS, Melisko M, Montoya JG, Mooney K, Moslehi JJ, O’Connor T, Overholser L, Paskett ED, Peppercorn J, Rodriguez MA, Ruddy KJ, Silverman P, Smith S, Syrjala KL, Tevaarwerk A, Urba SG, Wakabayashi MT, Zee P, Freedman-Cass DA, McMillian NR (2017) Survivorship, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 15(9):1140–1163CrossRefGoogle Scholar
  35. 35.
    Hill EK, Sandbo S, Abramsohn E, Makelarski J, Wroblewski K, Wenrich ER, McCoy S, Temkin SM, Yamada SD, Lindau ST (2011) Assessing gynecologic and breast cancer survivors’ sexual health care needs. Cancer 117(12):2643–2651CrossRefPubMedGoogle Scholar
  36. 36.
    Bober SL, Varela VS (2012) Sexuality in adult cancer survivors: challenges and intervention. J Clin Oncol 30(30):3712–3719CrossRefPubMedGoogle Scholar
  37. 37.
    Huffman LB, Hartenbach EM, Carter J, Rash JK, Kushner DM (2016) Maintaining sexual health throughout gynecologic cancer survivorship: a comprehensive review and clinical guide. Gynecol Oncol 140(2):359–368CrossRefPubMedGoogle Scholar
  38. 38.
    (2013) Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. American Psychiatric Association, Washington D.C.Google Scholar
  39. 39.
    Flynn KE, Lindau ST, Lin L, Reese JB, Jeffery DD, Carter J, Baron SR, Abramsohn E, Weinfurt KP (2015) Development and validation of a single-item screener for self-reporting sexual problems in U.S. adults. J Gen Intern Med 30(10):1468–1475CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    McGahuey CA et al (2000) The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 26(1):25–40CrossRefPubMedGoogle Scholar
  41. 41.
    Baser RE, Li Y, Carter J (2012) Psychometric validation of the Female Sexual Function Index (FSFI) in cancer survivors. Cancer 118(18):4606–4618CrossRefPubMedGoogle Scholar
  42. 42.
    Carter J et al (2017) Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline. J Clin Oncol JCO2017758995Google Scholar
  43. 43.
    Hummel SB, van Lankveld JJDM, Oldenburg HSA, Hahn DEE, Kieffer JM, Gerritsma MA, Kuenen MA, Bijker N, Borgstein PJ, Heuff G, Lopes Cardozo AMF, Plaisier PW, Rijna H, van der Meij S, van Dulken EJ, Vrouenraets BC, Broomans E, Aaronson NK (2017) Efficacy of Internet-based cognitive behavioral therapy in improving sexual functioning of breast cancer survivors: results of a randomized controlled trial. J Clin Oncol 35(12):1328–1340CrossRefPubMedGoogle Scholar
  44. 44.
    Jaspers L, Feys F, Bramer WM, Franco OH, Leusink P, Laan ETM (2016) Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Intern Med 176(4):453–462CrossRefPubMedGoogle Scholar
  45. 45.
    Laan E, Rellini AH, Barnes T, International Society for Sexual Medicine (2013) Standard operating procedures for female orgasmic disorder: consensus of the International Society for Sexual Medicine. J Sex Med 10(1):74–82CrossRefPubMedGoogle Scholar
  46. 46.
    Carter J, Goldfrank D, Schover LR (2011) Simple strategies for vaginal health promotion in cancer survivors. J Sex Med 8(2):549–559CrossRefPubMedGoogle Scholar
  47. 47.
    Carter J, Stabile C, Seidel B, Baser RE, Goldfarb S, Goldfrank DJ (2017) Vaginal and sexual health treatment strategies within a female sexual medicine program for cancer patients and survivors. J Cancer Surviv 11(2):274–283CrossRefPubMedGoogle Scholar
  48. 48.
    Bygdeman M, Swahn ML (1996) Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 23(3):259–263CrossRefPubMedGoogle Scholar
  49. 49.
    Costantino D, Guaraldi C (2008) Effectiveness and safety of vaginal suppositories for the treatment of the vaginal atrophy in postmenopausal women: an open, non-controlled clinical trial. Eur Rev Med Pharmacol Sci 12(6):411–416PubMedGoogle Scholar
  50. 50.
    Mytton J et al (2017) Removal of all ovarian tissue versus conserving ovarian tissue at time of hysterectomy in premenopausal patients with benign disease: study using routine data and data linkage. BMJ 356:j372CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    The Nams Hormone Therapy Position Statement Advisory Panel (2017) The 2017 hormone therapy position statement of the North American Menopause Society. Menopause 24(7):728–753CrossRefGoogle Scholar
  52. 52.
    Kaunitz AM, Manson JE (2015) Management of menopausal symptoms. Obstet Gynecol 126(4):859–876CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Bergendal A, Kieler H, Sundström A, Hirschberg AL, Kocoska-Maras L (2016) Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration. Menopause 23(6):593–599CrossRefPubMedGoogle Scholar
  54. 54.
    Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH (2010) A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 17(2):281–289CrossRefPubMedGoogle Scholar
  55. 55.
    Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EGB, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN (2007) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101(1):113–121CrossRefPubMedGoogle Scholar
  56. 56.
    Bordeleau L, Pritchard KI, Loprinzi CL, Ennis M, Jugovic O, Warr D, Haq R, Goodwin PJ (2010) Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol 28(35):5147–5152CrossRefPubMedGoogle Scholar
  57. 57.
    Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L (1998) Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 92(4 Pt 2):722–727PubMedGoogle Scholar
  58. 58.
    Del Carmen MG, Rice LW (2017) Management of menopausal symptoms in women with gynecologic cancers. Gynecol Oncol 146(2):427–435CrossRefPubMedGoogle Scholar
  59. 59.
    Lethaby A, Ayeleke RO, Roberts H (2016) Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 8:CD001500Google Scholar
  60. 60.
    American College of, O., P. Gynecologists’ Committee on Gynecologic, Farrell R (2016) ACOG Committee opinion no. 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol 127(3):e93–e96CrossRefGoogle Scholar
  61. 61.
    Sulaica E, Han T, Wang W, Bhat R, Trivedi MV, Niravath P (2016) Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy. Breast Cancer Res Treat 157(2):203–210CrossRefPubMedGoogle Scholar
  62. 62.
    Barton DL et al (2017) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care CancerGoogle Scholar
  63. 63.
    Benshushan A, Rojansky N, Chaviv M, Arbel-Alon S, Benmeir A, Imbar T, Brzezinski A (2009) Climacteric symptoms in women undergoing risk-reducing bilateral salpingo-oophorectomy. Climacteric 12(5):404–409CrossRefPubMedGoogle Scholar
  64. 64.
    Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, Gaarenstroom KN, Mourits MJE, Verheijen RHM, van Dorst EBL, van der Putten H, van der Velden K, Boonstra H, Aaronson NK (2005) Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 23(28):6890–6898CrossRefPubMedGoogle Scholar
  65. 65.
    Robson M, Hensley M, Barakat R, Brown C, Chi D, Poynor E, Offit K (2003) Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol Oncol 89(2):281–287CrossRefPubMedGoogle Scholar
  66. 66.
    Hooker GW, King L, VanHusen L, Graves K, Peshkin BN, Isaacs C, Taylor KL, Poggi E, Schwartz MD (2014) Long-term satisfaction and quality of life following risk reducing surgery in BRCA1/2 mutation carriers. Hereditary Cancer in Clinical Practice 12(1):9–9CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Kotsopoulos J, Huzarski T, Gronwald J, Moller P, Lynch HT, Neuhausen SL, Senter L, Demsky R, Foulkes WD, Eng C, Karlan B, Tung N, Singer CF, Sun P, Lubinski J, Narod SA (2016) Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case–control study. Breast Cancer Res Treat 155(2):365–373CrossRefPubMedGoogle Scholar
  68. 68.
    Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van ‘t Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL, PROSE Study Group (2005) Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23(31):7804–7810CrossRefPubMedGoogle Scholar
  69. 69.
    Domchek S, Kaunitz AM (2016) Use of systemic hormone therapy in BRCA mutation carriers. Menopause 23(9):1026–1027CrossRefPubMedGoogle Scholar
  70. 70.
    Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, Kim-Sing C, Neuhausen SL, Gilbert L, Ghadirian P, Manoukian S, Rennert G, Friedman E, Isaacs C, Rosen E, Rosen B, Daly M, Sun P, Narod SA, the Hereditary Breast Cancer Clinical Study Group (2008) Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 100(19):1361–1367CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyVirginia Commonwealth University Health SystemRichmondUSA
  2. 2.Johns Hopkins University School of MedicineBaltimoreUSA
  3. 3.Children’s Hospital of PhiladelphiaPhiladelphiaUSA
  4. 4.Memorial Sloan Kettering Cancer CenterNew YorkUSA
  5. 5.University of FloridaJacksonvilleUSA

Personalised recommendations